DailyDoctor Archive Specialties Get app
All infectious diseases briefings

The edition · Infectious Diseases

Shorter TB prevention for children: better completion, and fewer cases with 4HR

A network meta-analysis favours rifamycin-based short courses over nine months of isoniazid; asymptomatic mpox looks uncommon, and one in six pregnant women in Asia-Pacific carry group B strep.

The edition in brief

A network meta-analysis of 11 randomised trials in children and adolescents with TB infection found that four months of isoniazid and rifampicin (4HR) halved active TB compared with nine months of isoniazid (RR 0.49, 95% CI 0.32–0.76). Short courses — 3HP, 4HR and 4R — all had higher completion, and 4R had fewer adverse reactions than 9H, while 3HP had more than 4HR or 4R. The certainty is limited by a sparse, partly disconnected network. A meta-analysis of studies from 2022 to 2024 put asymptomatic mpox detection at about 1% in non-endemic regions, though with a wide prediction interval and no data on whether such people transmit. Across 98 studies and nearly one million pregnant women in the Asia-Pacific region, group B streptococcus colonisation was 18%, serotype III was commonest, and beta-lactam resistance was 0–2%, so penicillin remains reliable for intrapartum prophylaxis. The FDA lists a Class II recall of Baxter's premixed vancomycin in dextrose bags for manufacturing-practice deviations. The pearl is the step that must precede any TB preventive therapy: excluding active disease.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free